Breaking Finance News

JPMorgan announced Athenex (NASDAQ:ATNX), hiking its price target to $22.20 earlier today

Yesterday Athenex (NASDAQ:ATNX) traded 0.23% higher at $17.04. The company’s 50-day moving average is $17.59 and its 200-day moving average is $16.80. The last stock close price is up 1.68% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time. 24,356 shares of the stock were exchanged, down from an average trading volume of 152,133

Reporting a possible upside of 0.30%, JPMorgan increased the stock price target of Athenex (NASDAQ:ATNX) to $22.20

Previously on 09/18/2017, Credit Suisse reported about Athenex (NASDAQ:ATNX) raised the target price from $0.00 to $25.00. At the time, this indicated a possible upside of 0.48%.

See Chart Below

Athenex (NASDAQ:ATNX)

Athenex has a with a one year low of $11.21 and a one year high of $20.79 ATNX’s total market value is presently $0.

More About Athenex (NASDAQ:ATNX)

Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company's Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.